65 results about "Acidic Fibroblast Growth Factor" patented technology

The present invention provides muscle-derived cells, preferably myoblasts and muscle-derived stem cells, genetically engineered to contain and express one or more heterologous genes or functional segments of such genes, for delivery of the encoded gene products at or near sites of musculoskeletal, bone, ligament, meniscus, cartilage or genitourinary disease, injury, defect, or dysfunction. Ex vivo myoblast mediated gene delivery of human inducible nitric oxide synthase, and the resulting production of nitric oxide at and around the site of injury, are particularly provided by the invention as a treatment for lower genitourinary tract dysfunctions. Ex vivo gene transfer for the musculoskeletal system includes genes encoding acidic fibroblast growth factor, basic fibroblast growth factor, epidermal growth factor, insulin-like growth factor, platelet derived growth factor, transforming growth factor-β, transforming growth factor-α, nerve growth factor and interleukin-1 receptor antagonist protein (IRAP), bone morphogenetic protein (BMPs), cartilage derived morphogenetic protein (CDMPs), vascular endothelial growth factor (VEGF), and sonic hedgehog proteins.

An engineered, purified polypeptide of acidic fibroblast growth factor (FGF-1) is described, the amino acid sequence of which consists essentially of SEQ ID NO: 1. The engineered polypeptide provides 70 times the mitogenic activity of wild type acidic fibroblast growth factor. Other engineered FGFs are also described, having altered properties, including reduced heparin binding affinity and increased mitogenicity as demonstrated with a model mammalian cell line derived from mice, NIH 3T3 fibroblasts.

A modified human acidic fibroblast growth factor gene is disclosed. The nucleotide sequence of the gene is shown as the number 25 locus to the number 450 locus of SEQ ID NO.1. The sequence is designed according to codon preferences of bombyx mori, and can be normally expressed and translated in the bombyx mori. A recombinant vector containing the modified human acidic fibroblast growth factor gene is also disclosed. The recombinant vector comprises an enhanser hr3 and a secreting type sericin 1 promoter Ser1, specifically expresses a modified human acidic fibroblast growth factor in a middle silk gland cell of the bombyx mori, and secretes a recombinant protein to a sericin layer of silk. The obtained silk has bioactivity, has a function of promoting cell proliferation when the silk is directly used, and is a good medical material.

The invention discloses a gene for modifying a human acidic fibroblast growth factor applied to silkworm silk gland expression, and an expression system and application of the gene. The gene for modifying the human acidic fibroblast growth factor is represented by the 7-450 site of SEQ ID NO.1; the amino acid coded by the gene is represented by SEQ ID NO.2; the gene for modifying the human acidic fibroblast growth factor, a gene promoter of secretory type sericin 1 and a gene terminator of the secretory type sericin 1 form an expression box, and the expression box is expressed by using an enhancer hr3 in an enhanced manner; simultaneously, the expression system is constructed by accessing a piggyBac transposable arm and a fluorescent selected and marked gene. The expression system is capable of expressing and recombining the human acidic fibroblast growth factor in silkworm silk gland at high efficiency; furthermore, the expression system has biological activity and can be used for producing and recombining the human acidic fibroblast growth factor in a large scale, therefore, the expression system has good market prospects.

The invention relates to the field of biotechnologies, in particular to application of lettuce used as a host to expressing growth factors. The human acidic fibroblast growth factors (FGF-1) and the basic fibroblast growth factors (FGF-2) are expressed by the aid of recombinant vectors and agrobacterium tumefaciens mediated vacuum infiltration methods. Expression systems can be collected after the fact that plant exogenous proteins are infected in agrobacterium tumefaciens for 4 d is confirmed. Successful expression of recombinant FGF-1 and FGF-2 is confirmed by the aid of SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) methods and western blotting methods (Western methods). The biological activity of the FGF-1 and the FGF-2 which are produced by the lettuce is provided by cell proliferation experiments. The application has the advantage that methods for producing large quantities of the active recombinant human FGF-1 and FGF-2 are low in cost and are convenient.

The invention discloses an antibiotic peptide, blood coagulation apoenzyme slicing sequence and fusion protein sequence of phoroblast growth factor, wherein the antibiotic peptide can be bacteria resistant peptide, antimycotic peptide, or genetic engineering hybrid peptide for bacteria and fungus resistant simultaneously, while the phoroblast growth factor can be acidic phoroblast growth factor (aFGF) or basic fibroblast growth factor (bFGF), the nucleic acid sequence for coding the fusion protein can be inserted into appropriate expression carrier and expressed in Pichia pastoris yeast.

The invention discloses a human stem cell factor skin repairing solution and a preparation method thereof. The solution is prepared from the following components by content: 50-75ug/l of epidermal growth factor, 15-20ug/l of acidic fibroblast growth factor, 15-20ug/l of basic fibroblast growth factor and 4-6ug/l of vascular endothelial growth factor. A series of cell factors against quick proliferation of germinal cells, and the effects of quickly repairing damaged skin and repairing skin quality can be achieved according to reasonable environment which accords with human cell growth and accelerating growth.

The invention relates to a recombination food-grade lactic acid bacterium for secreting and expressing a fusion protein containing a human acidic fibroblast growth factor, a preparation method of the recombination food-grade lactic acid bacterium, and in particular relates to a method for carrying out fusion expression by using a Usp45 protein signal peptide, a secretion-promoting protein peptide and the human acidic fibroblast growth factor. According to the invention, genes for coding the fusion proteins are cloned to a lactic acid bacterium constitutive expression vector pMG36m, then transformed into lactococcus lactis NZ9000, and subjected to recombinant screening by using melibiose as a carbon source. The recombination lactic acid engineering bacterium can continuously secret the fusion protein containing the human acidic fibroblast growth factor in a fermentation expression process. The invention relates to an application of the recombination food-grade lactic acid bacterium in the preparation of cosmetics and medicines or foods for preventing and treating human ulcerative colitis.

This invention discloses a method for producing liver cells by inducing haemopoietic stem cells in vitro, comprising: inoculating the haemopoietic stem cells or CD34+ cells into the culture media containing embryonic bovine serum, human stem cell factor, human interleukins 3(IL-3), interleukins 6(IL-6), human liver cell growth factor, human epidermal growth factor(EGF), human acdic fibroblast growth factor, human basic fibroblast growth factor(bFGF), human leukemia inhibitory factor(LIF) and oncostatin M(OSM), and inducing the producing of liver cells in vitro. By applying the method of this invention to induce liver cells from the haemopoietic stem cells, it can acquire a high proportion of liver cells in the culture with good effects.

The invention discloses a culturing medium for cultivating animal cells without serum and with low density and an application thereof. The culturing medium for cultivating animal cells without serum and with low density is characterized in that synthetic culturing medium is adopted as the raw material, and insulin powder, transferrin powder, L-glutamine powder, sodium selenite powder, ethanolamine solution, lipid solution, epidermal growth factor powder, a recombinant human acidic fibroblast growth factor, vitamin solution, plant hydrolysate solution, putrescine, ferrous sulfate, hydrocortisone and an insulin-like factor are added into the synthetic culturing medium. The culturing medium can be suitable for the growth and metabolism and product expression of the cells of the mammals in the condition of low density without the serum. Combined with the method that D- polylysine powder is coated on a culture plate with 96 holes, the use of the culturing medium for cultivating animal cells without serum and with low density can clone the animal cells without the serum, thereby realizing the continuity of cultivating the animal cells without the serum, improving the stability of product expression, assuring the quality and safety of the product, and enhancing the controllability of the production process. Thus, the culturing medium for cultivating animal cells without serum and with low density has wide application range.

The invention relates to an aerosol preparation produced by restructured human acidic desmocyte growth factor for treating wound surface assimilation and refractoriness ulcer. The preparation by the invention has good stableness and substantial clinical curative effect. íí

The present invention is gene recombination process, in which human acidic fibroblast growth factors (haFGF) and oil-body protein gene are fused and synthesized to constitute one plant oil-body expressing vector and establish oil-body protein genetically transforming and expressing system. Root nodule agrobacterium is used to transform Arabidopsis thalianuum, safflower, soybean, black bean and rape to obtain transgenic plant. The molecular biology detection on transgenic safflower and rape proves the integration and expression of exogenous gene, and the activity detection proves the bioactivity corresponding to the standard haFGF activity of obtained recombinant protein. The present invention also provides the method of expressing aFGF in plant seed, and the method may be used in producing aFGF at low cost and developing new medicine.

The invention relates to a simple and convenient chemical industrial technology for prokaryotic expression and purification of humanized acidic fibroblast growth factor (aFGF), and aims to construct engineering bacteria of recombinant haFGF (Human Acidic Fibroblast Growth Factor) gene by using a recombinant DNA (Deoxyribonucleic Acid) technology, realize expression of a large amount of humanized FGF-1 in prokaryotic cells and obtain a target gene with higher purity through simple purification steps. haFGF is produced by using the biological engineering method, so that the technology has the advantages of easiness in forming scale production capacity, high yield and low cost.

The present invention discloses a user of acidic fibroblast growth factor in preparing cosmetics, and simultaneously provides a production process. The invention uses biotechnology for beautifying. The acidic fibroblast growth factor is used for external beautifying. The physiologic status of skin is improved at root and the restoring and metabolism of epidermic tissue are promoted through complementing the biological active factors which promote the metabolism and proliferation of epidermic cell. The skin can be smoothed and young. The color spot is faded and the wrinkle is pacified. The damage of sunshine to the skin is reduced. The skin smoothing and beautifying effect is obvious. Furthermore the acidic fibroblast growth factor is safe and reliable without side effect.

The invention discloses a method for realizing instant expression of acidic fibroblast growth factors in plant, relating to an improvement in the process for making acidic fibroblast growth factor and further belonging to the plant genetic engineering technical field. The method is as follows: firstly, the construction of the plant virus expression vector of anthropogenic acidic fibroblast growth factors is carried out; a coded anthropogenic acidic fibroblast growth factor DNA sequence 468bp is connected with a reconstructive plant virus expression vector, and then is transformed to agrobacterium GV3101 so as to be used in the instant expression in plant; a plant material of proper seedling age is selected to carry out agrobacterium infection, that is, slight scars are respectively scraped at both sides of a main vein on the back side of a leaf by a syringe needle; then, bacterial liquid is injected into the leaf from the scars by a syringe with the needle removed so as to ensure that plant virus carrying target gene hafgf can be quickly diffused, expressed and aggregated in a plant body; when the aggregation reaches to a peak value, plants are collected to carry out the extraction of target protein.

The invention relates to recombinant human acidic fibroblast growth factor (FGF1), in particular relates to a preparation method of FGF1 full-length protein by utilizing escherichia coli, which comprises the following steps of amplifying by utilizing a PCR (polymerase chain reaction) method to obtain a human FGF1 full-length gene PCR product; and digesting the PCR product by using incision enzyme. According to the preparation method, the full-length gene of the human acidic fibroblast growth factor is cloned to a pMAL-p5X expression carrier; the recombinant plasmid expresses the FGF1 full-length protein containing MBP (myelin basic protein) fusion label at high efficiency in the escherichia coli, wherein the protein in soluble expression; and the protein with MBP infusion label is purified by utilizing an MBP affinity column, and a complete FGF1 protein without the fusion label is prepared by utilizing TEV (tobacco etch virus) enzyme binding site and using TEV digested and purified infusion protein. The FGF1 full-length protein has high solubility and higher purity.

The present invention relates to the treatment of coronary heart disease by revascularization therapy, and more particularly to the intramyocardial injection of a pharmaceutical composition comprising a recombinant fibroblast growth factor-1 protein or a fragment of a recombinant fibroblast growth factor-1 protein, optionally, with a physiologic glue for inducing local neoangiogenesis in ischemic myocardium. Methods of producing the recombinant fibroblast growth factor 1 protein and fragments are also disclosed.

The invention provides a production method and use of a novel fusion protein, in particular a human acidic fibroblast growth factor variant fusion protein and its preparing process, wherein the fusion protein is the fusion of human acidic fibroblast growth factor variant with thioredoxin, the fusion protein can be used for the treatment of wound healing.

The spray for treating burns, scalds and chronic ulcer has PEG-aFGF decorated chemically with polyethylene glycol as acid fibroblast growth factor as main medicinal component. The spray contains mainly PEG-aFGF decorated chemically with polyethylene glycol as acid fibroblast growth factor 1-100 microgram, hot zedoary oil 1-100 mg, protecting agent 0.001-0.05 mg, preservative 0.001-0.01 mg, stabilizer 0.0001-0.001 mg and corrective 0.01-0.2 mg in each milliliter, and the rest is physiological saline or water for injection. The spray has high stability, long biological half time, high safety and other features.

The invention discloses an artificial polypeptide capable of inducing bone mesenchymal stem cells to differentiate into hepatic cells and a biological product of such artificial polypeptide. The artificial polypeptide is a polypeptide containing an amino acid sequence shown in formula (IV): LGENQPDAK(Xa)PCFQEDPMA(Xb)GTDCTLMEIWN, (IV), wherein each of Xa and Xb is selected from M, Y, L, V, W or E. Professionals in the field know that a strong ability to induce the bone mesenchymal stem cells to differentiate into the hepatic cells is achieved in case of combination of acidic fibroblast growth factor, hepatocyte growth factor and oncostatin M, and after induced culture for 14 days, alpha fetal protein mRNA and albumin mRNA in the cells are in remarkably positive expression. It is proven that the artificial polypeptide with the same effect is capable of inducing the bone mesenchymal stem cells to differentiate into the hepatic cells, and accordingly the artificial polypeptide can be prepared into the biological product for inducing the bone mesenchymal stem cells to differentiate into the hepatic cells.

The invention relates to a single-chain antibody gene, recombinant vector and expressing product of anti-human acid desmocyte growth factor in the field of gene project technology. It provides a single-chain Fv which has real value. ScFv is a signal chain which is formed by two variable areas of a light chain and a heavy chain. It folds the two variable areas whose non-covalent bond forms the section with antigen conjugated function.